Mazur, Natalie INatalie IMazurHiggins, DeborahDeborahHigginsNunes, Marta CMarta CNunesMelero, José AJosé AMeleroLangedijk, Annefleur CAnnefleur CLangedijkHorsley, NicoleNicoleHorsleyBuchholz, Ursula JUrsula JBuchholzOpenshaw, Peter JPeter JOpenshawMcLellan, Jason SJason SMcLellanEnglund, Janet AJanet AEnglundMejias, AsuncionAsuncionMejiasKarron, Ruth ARuth AKarronSimões, Eric AfEric AfSimõesKnezevic, IvanaIvanaKnezevicRamilo, OctavioOctavioRamiloPiedra, Pedro APedro APiedraChu, Helen YHelen YChuFalsey, Ann RAnn RFalseyNair, HarishHarishNairKragten-Tabatabaie, LeylaLeylaKragten-TabatabaieGreenough, AnneAnneGreenoughBaraldi, EugenioEugenioBaraldiPapadopoulos, Nikolaos GNikolaos GPapadopoulosVekemans, JohanJohanVekemansPolack, Fernando PFernando PPolackPowell, MairMairPowellSatav, AshishAshishSatavWalsh, Edward EEdward EWalshStein, Renato TRenato TSteinGraham, Barney SBarney SGrahamBont, Louis JLouis JBontRespiratory Syncytial Virus Network (ReSViNET) Foundation2018-07-202018-10-01Lancet Infectious Diseases, 2018, 18 (10), pp.e295-e3111473-3099http://hdl.handle.net/10044/1/61037The global burden of disease caused by respiratory syncytial virus (RSV) is increasingly recognised, not only in infants, but also in older adults (aged ≥65 years). Advances in knowledge of the structural biology of the RSV surface fusion glycoprotein have revolutionised RSV vaccine development by providing a new target for preventive interventions. The RSV vaccine landscape has rapidly expanded to include 19 vaccine candidates and monoclonal antibodies (mAbs) in clinical trials, reflecting the urgency of reducing this global health problem and hence the prioritisation of RSV vaccine development. The candidates include mAbs and vaccines using four approaches: (1) particle-based, (2) live-attenuated or chimeric, (3) subunit, (4) vector-based. Late-phase RSV vaccine trial failures highlight gaps in knowledge regarding immunological protection and provide lessons for future development. In this Review, we highlight promising new approaches for RSV vaccine design and provide a comprehensive overview of RSV vaccine candidates and mAbs in clinical development to prevent one of the most common and severe infectious diseases in young children and older adults worldwide.© 2018 Elsevier Ltd. All rights reserved. This manuscript is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International http://creativecommons.org/licenses/by-nc-nd/4.0/Science & TechnologyLife Sciences & BiomedicineInfectious DiseasesF NANOPARTICLE VACCINESMALL HYDROPHOBIC PROTEINANTIGENIC SITE IIT-CELL IMMUNITYYOUNG-CHILDRENATTACHMENT PROTEINDISEASE SEVERITYHEALTHY WOMENRSV INFECTIONPOSTFUSION FAntibodies, MonoclonalAntibodies, ViralGlobal HealthHumansNanoparticlesRespiratory Syncytial Virus InfectionsRespiratory Syncytial Virus VaccinesWorld Health OrganizationRespiratory Syncytial Virus Network (ReSViNET) FoundationHumansRespiratory Syncytial Virus InfectionsRespiratory Syncytial Virus VaccinesAntibodies, MonoclonalAntibodies, ViralWorld Health OrganizationNanoparticlesGlobal HealthMicrobiology1103 Clinical Sciences1108 Medical MicrobiologyJournal Articlehttps://www.dx.doi.org/10.1016/S1473-3099(18)30292-51474-4457